Clinical Research Network on Antimicrobial Resistance (UM1 Clinical Trial Required)

Summary

The National Institute of Allergy and Infectious Diseases (NIAID) seeks to advance its mission by continuing support for a Clinical Research Network on Antimicrobial Resistance (AMR). AMR is a major health challenge that limits treatment options and allows resistant infections to persist. Individuals with chronic conditions like diabetes and cancer are particularly vulnerable, resulting in increased illness and death as well as higher healthcare costs in the United States. The program aims to design, implement, and manage clinical research addressing key clinical questions in AMR. Research will focus on bacterial and fungal infections associated with AMR. Areas of emphasis include clinical testing of new antibiotics and other treatments such as bacteriophage therapy, methods optimizing the use of existing antibiotics, evaluating novel diagnostic tests including using diagnostics to refine treatment strategies, and mentoring the next generation of AMR clinical researchers. Grant authorities that allow NIAID to forecast this opportunity are as follows: Sections 301 and 405 of the Public Health Service Act as amended (42 USC 241 and 284) and under Federal Regulations 42 CFR Part 52 and 2 CFR Part 200.

Eligibility

• Other
• Native American Tribal Organizations Other Than Federally Recognized Tribal Governments
• For Profit Organizations Other Than Small Businesses
• Nonprofits Non Higher Education Without 501c3
• Special District Governments
• City Or Township Governments
• Nonprofits Having A 501(c)(3) Status With the Irs Other Than Institutions of Higher Education
• Public and State Institutions of Higher Education
• Small Businesses
• Private Institutions of Higher Education

Funding categories

• Health